Maha Hussain, MD, on Next-Generation Sequencing of Prostate Tumor Tissue: Results From the PROfound Study

February 19, 2020 By The ASCO Post Staff

Maha Hussain, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses the first phase III clinical trial to demonstrate the feasibility of tissue-based genomic testing to preselect men with metastatic castration-resistant prostate cancer for targeted treatment and the superiority of the PARP inhibitor olaparib compared to enzalutamide or abiraterone (Abstract 195).

Related Content